Masimo (NASDAQ:MASI) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Masimo (NASDAQ:MASI) announced its earnings results on Tuesday. The medical equipment provider reported $1.32 EPS for the quarter, topping the consensus estimate of $1.20 by $0.12, Zacks reports. The business had revenue of $371.50 million during the quarter, compared to the consensus estimate of $366.89 million. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. Masimo’s revenue was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.86 EPS. Masimo updated its FY 2025 guidance to 5.620-5.790 EPS.

Masimo Price Performance

NASDAQ:MASI traded down $0.06 on Thursday, hitting $142.09. The company had a trading volume of 257,570 shares, compared to its average volume of 647,431. The stock has a market capitalization of $7.72 billion, a price-to-earnings ratio of -16.69 and a beta of 1.28. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57. The firm has a 50 day moving average of $144.91 and a two-hundred day moving average of $153.96. Masimo has a 52 week low of $133.70 and a 52 week high of $194.88.

Analyst Upgrades and Downgrades

MASI has been the subject of a number of recent research reports. Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. BTIG Research reissued a “buy” rating and issued a $198.00 price objective on shares of Masimo in a report on Wednesday. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Finally, Piper Sandler boosted their price objective on shares of Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $194.00.

Insider Buying and Selling

In related news, Director William R. Jellison acquired 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was acquired at an average price of $145.98 per share, with a total value of $437,940.00. Following the purchase, the director directly owned 4,790 shares in the company, valued at approximately $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Masimo

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its stake in Masimo by 44.5% in the 1st quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock valued at $7,311,000 after purchasing an additional 13,513 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Masimo by 517.2% during the second quarter. AQR Capital Management LLC now owns 50,256 shares of the medical equipment provider’s stock valued at $8,454,000 after acquiring an additional 42,114 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Masimo by 8.9% during the second quarter. The Manufacturers Life Insurance Company now owns 58,714 shares of the medical equipment provider’s stock valued at $9,877,000 after acquiring an additional 4,814 shares during the last quarter. California Public Employees Retirement System raised its stake in shares of Masimo by 4.2% during the second quarter. California Public Employees Retirement System now owns 72,807 shares of the medical equipment provider’s stock valued at $12,248,000 after acquiring an additional 2,932 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Masimo by 38.6% during the first quarter. Goldman Sachs Group Inc. now owns 280,255 shares of the medical equipment provider’s stock valued at $46,690,000 after acquiring an additional 78,003 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.